Arylacenamide

Identification

Generic Name
Arylacenamide
DrugBank Accession Number
DB05792
Background

Arylacenamide (SR31747) is a peripheral [sigma] ligand that binds four proteins in human cells, i.e. SRBP-1, [sigma]-2, HSI and its relative SRBP-2. It is a dual agent with both immunomodulatory and antiproliferative activities.

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 396.437
Monoisotopic: 395.214655539
Chemical Formula
C23H35Cl2N
Synonyms
Not Available
External IDs
  • SR 31747
  • SR-31747

Pharmacology

Indication

Investigated for use/treatment in cancer/tumors (unspecified), immunosuppressive, and prostate cancer.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action

SR31747 blocks proliferation of human lymphocytes, modulates the expression of pro- and anti-inflammatory cytokines, and was shown to protect animals in vivo against acute and chronic inflammatory conditions such as acute graft-versus-host reaction, lethality induced by staphylococcal enterotoxin B and lipopolysaccharide or rheumatoid arthritis. Besides these immunomodulatory activities, the molecule also inhibits the proliferation of various tumor cell lines in vitro in a time- and concentration-dependent manner.

TargetActionsOrganism
UHCG20471, isoform CRA_cNot AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as styrenes. These are organic compounds containing an ethenylbenzene moiety.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Styrenes
Direct Parent
Styrenes
Alternative Parents
Cyclohexylamines / Chlorobenzenes / Aryl chlorides / Trialkylamines / Organopnictogen compounds / Organochlorides / Hydrochlorides / Hydrocarbon derivatives
Substituents
Amine / Aromatic homomonocyclic compound / Aryl chloride / Aryl halide / Chlorobenzene / Cyclohexylamine / Halobenzene / Hydrocarbon derivative / Hydrochloride / Organic nitrogen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
9K6U3I1UR0
CAS number
132173-07-0
InChI Key
HKHPCMBPASXYGP-KVVVOXFISA-N
InChI
InChI=1S/C23H34ClN.ClH/c1-2-25(21-13-7-4-8-14-21)17-9-10-19-15-16-22(23(24)18-19)20-11-5-3-6-12-20;/h9-10,15-16,18,20-21H,2-8,11-14,17H2,1H3;1H/b10-9-;
IUPAC Name
N-[(2Z)-3-(3-chloro-4-cyclohexylphenyl)prop-2-en-1-yl]-N-ethylcyclohexanamine hydrochloride
SMILES
Cl.CCN(C\C=C/C1=CC(Cl)=C(C=C1)C1CCCCC1)C1CCCCC1

References

General References
  1. Paul R, Silve S, De Nys N, Dupuy PH, Bouteiller CL, Rosenfeld J, Ferrara P, Le Fur G, Casellas P, Loison G: Both the immunosuppressant SR31747 and the antiestrogen tamoxifen bind to an emopamil-insensitive site of mammalian Delta8-Delta7 sterol isomerase. J Pharmacol Exp Ther. 1998 Jun;285(3):1296-302. [Article]
  2. Casellas P, Galiegue S, Bourrie B, Ferrini JB, Jbilo O, Vidal H: SR31747A: a peripheral sigma ligand with potent antitumor activities. Anticancer Drugs. 2004 Feb;15(2):113-8. [Article]
PubChem Compound
6439330
PubChem Substance
175427033
ChemSpider
4943746

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.93e-05 mg/mLALOGPS
logP7.48ALOGPS
logP7.4Chemaxon
logS-7.3ALOGPS
pKa (Strongest Basic)9.95Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count1Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area3.24 Å2Chemaxon
Rotatable Bond Count6Chemaxon
Refractivity111.68 m3·mol-1Chemaxon
Polarizability44.21 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9704
Caco-2 permeable+0.6889
P-glycoprotein substrateSubstrate0.6038
P-glycoprotein inhibitor IInhibitor0.8012
P-glycoprotein inhibitor IIInhibitor0.6996
Renal organic cation transporterInhibitor0.6689
CYP450 2C9 substrateNon-substrate0.7062
CYP450 2D6 substrateNon-substrate0.5748
CYP450 3A4 substrateSubstrate0.5727
CYP450 1A2 substrateInhibitor0.8699
CYP450 2C9 inhibitorNon-inhibitor0.8809
CYP450 2D6 inhibitorInhibitor0.7277
CYP450 2C19 inhibitorInhibitor0.7907
CYP450 3A4 inhibitorNon-inhibitor0.8447
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9049
Ames testNon AMES toxic0.7998
CarcinogenicityNon-carcinogens0.6462
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.7869 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5173
hERG inhibition (predictor II)Inhibitor0.8518
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-186.56691
predicted
DeepCCS 1.0 (2019)
[M+H]+188.92491
predicted
DeepCCS 1.0 (2019)
[M+Na]+195.82036
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Not Available
Specific Function
Not Available
Gene Name
SIGMAR1
Uniprot ID
Q5T1J1
Uniprot Name
HCG20471, isoform CRA_c
Molecular Weight
14852.655 Da

Drug created at November 18, 2007 18:27 / Updated at June 12, 2020 16:52